23. April 2019
AD HOC ANNOUNCEMENT Marinomed Biotech AG announces top line results of the Phase III study for Budesolv:
Marinomed Biotech AG, a globally active biopharmaceutical company with headquarters in Vienna, has announced the successful completion of the pivotal Phase III study for Budesolv. The top line results are now available and show that Budesolv achieves at least the same effect as the product which is currently on the market, with a significantly lower dose.